IBRANDS CORPORATION

iBrands Corporation Appoints New CEO And Changes Business Focus

Retrieved on: 
Monday, June 7, 2021

LAS VEGAS, June 07, 2021 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holdings company, is pleased to announce the appointment of Billionaire Frank Ekejija as its new Chairman, President and CEO and changed the companys business focus, respectively.

Key Points: 
  • LAS VEGAS, June 07, 2021 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holdings company, is pleased to announce the appointment of Billionaire Frank Ekejija as its new Chairman, President and CEO and changed the companys business focus, respectively.
  • iBrands Corporation has an enormous intrinsic value because we have loaded the basis for the benefit of the shareholders and stakeholders.
  • iBrands Corporation is well capitalized to support our admitted partners and clients operations around the world.
  • We are strategically situated and positioned to serve the capital markets, said Frank Ekejija, new Chairman, President and CEO of iBrands Corporation.

iBrands Corporation Launches Nano Sport Nutraceutical

Retrieved on: 
Monday, May 10, 2021
Drugs, Cannabinoids, Resorcinols, Natural phenols, Anticonvulsants, Cannabidiol

b'LAS VEGAS, May 10, 2021 (GLOBE NEWSWIRE) -- (OTC PINK:\xc2\xa0IBRC) ("the Company"), a diversified holding and branding company, announces that through its subsidiary iBrands Farms, has launched Nano Sport, a Nano Stilbene and Nano Cannabidiol based nutraceutical product.\nNano Cannabidiol is a proprietary formulation of nano particle cannabidiol isolate in the range of 75-90 nanometers at a concentration of 200mg per milliliter.

Key Points: 
  • b'LAS VEGAS, May 10, 2021 (GLOBE NEWSWIRE) -- (OTC PINK:\xc2\xa0IBRC) ("the Company"), a diversified holding and branding company, announces that through its subsidiary iBrands Farms, has launched Nano Sport, a Nano Stilbene and Nano Cannabidiol based nutraceutical product.\nNano Cannabidiol is a proprietary formulation of nano particle cannabidiol isolate in the range of 75-90 nanometers at a concentration of 200mg per milliliter.
  • "In our opinion, the small size, combined with the stability of the formulation, positions our NanoStilbene and Nano Cannabidiol product as second-to-none in terms of effectively delivering the compound for a variety of uses.
  • Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one\'s immune system.
  • Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.

iBrands Corporation Becomes Product Sponsor For Professional Football Franchise

Retrieved on: 
Monday, May 3, 2021
Health sciences, Health, Drug discovery, Clinical research, Pharmaceutical industry, Food science, Nutraceutical, Pharmacy, Clinical trial, Immunotherapy, Cannabinoid

The clinical trial is listed on the National Institutes of Health Clinical Trial Database at www.clinicaltrials.gov.\nThese statements have not been evaluated by the Food and Drug Administration.

Key Points: 
  • The clinical trial is listed on the National Institutes of Health Clinical Trial Database at www.clinicaltrials.gov.\nThese statements have not been evaluated by the Food and Drug Administration.
  • Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one\'s immune system.
  • Our mission is to efficiently deliver the highest quality industrial hemp-derived cannabinoid products and unique nutraceuticals to our customers, both retail and wholesale.
  • Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.

iBrands Corporation Provides Update to Shareholders

Retrieved on: 
Tuesday, March 30, 2021
Clinical trials, ClinicalTrials.gov

LAS VEGAS, March 30, 2021 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC PINK:IBRC) ("the Company"), a diversified holding and branding company, announces a update to shareholders and interested parties.

Key Points: 
  • LAS VEGAS, March 30, 2021 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC PINK:IBRC) ("the Company"), a diversified holding and branding company, announces a update to shareholders and interested parties.
  • A clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is now on the Federal Clinical Trial registry: https://www.clinicaltrials.gov/ct2/show/NCT04421391 .
  • We want to wish for the safety and health of our shareholders and their families at this time and thank you for your continued faith in iBrands Corporations future.
  • iBrands Farms is a vertically integrated agribusiness focused on the production and sale of hemp derived products with naturally occurring cannabinoids.

iBrands Corporation Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies

Retrieved on: 
Monday, June 29, 2020
Branches of biology, Kynurenine, Inflammation, Lipopolysaccharide

In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression.

Key Points: 
  • In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression.
  • Mice receiving LPS suffered a reduction in memory activity, as quantified using the Morris Water Maze test.
  • Administration of QuadraMune significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine.
  • Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression [1].

iBrands Corporation Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer

Retrieved on: 
Monday, June 22, 2020
Branches of biology, Immunology, Immune system, Biology

LAS VEGAS, June 22, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces novel data suggesting that QuadraMune administration reduces the number and activity of immune inhibitory cells termed "myeloid suppressor cells."

Key Points: 
  • LAS VEGAS, June 22, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces novel data suggesting that QuadraMune administration reduces the number and activity of immune inhibitory cells termed "myeloid suppressor cells."
  • "The patent that we previously filed with the Company possessed data showing that QuadraMune suppresses inflammatory molecules which act to deteriorate antiviral immunity.
  • "In the current patent, we cover the use of QuadraMune to reduce these immune inhibitory cells, called Myeloid Suppressor cells, which act as cancer's shield against the immune response."
  • "Myeloid Suppressor Cells, originally described by Dr. Sharwan Singhal as "Natural Suppressor" cells, have been shown to correlate with faster cancer death and treatment unresponsiveness," said Timothy Dixon, President, and CEO of the Company.

iBrands Corporation Announces Clinical Trial For Immune Booster Product

Retrieved on: 
Wednesday, June 17, 2020
Health, Clinical research, Medical research, Articles, Clinical pharmacology, Clinical trial, Design of experiments, Pharmaceutical industry

LAS VEGAS, June 17, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces clinical trial for Quadramune, the Companys featured immune boosting nutraceutical product on its online store.

Key Points: 
  • LAS VEGAS, June 17, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces clinical trial for Quadramune, the Companys featured immune boosting nutraceutical product on its online store.
  • The Company's nutraceutical manufacturer, Therapeutics Solutions International, Inc. (TSOI), announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting formulation QuadraMune.
  • Last week the TSOI announced data from a preliminary clinical trial in which four groups of eight volunteers were treated with placebo or escalating doses of QuadraMune[1].
  • The new clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is now on the Federal Clinical Trial registry: https://www.clinicaltrials.gov/ct2/show/NCT04421391
    These statements have not been evaluated by the Food and Drug Administration.

iBrands Corporation Adds Immune Booster To Nutraceutical Product Line

Retrieved on: 
Monday, April 27, 2020
Health, Articles, Medical specialties, Immunology, Vaccination, Food science, Nutraceutical, Nutrition, Pharmacy, Hemp, Immunity, Cannabinoid

LAS VEGAS, April 27, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces that it has, through its wholly owned subsidiary iBrands Farms, added QuadraMune, an all natural immune booster to its nutraceutical product line.

Key Points: 
  • LAS VEGAS, April 27, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces that it has, through its wholly owned subsidiary iBrands Farms, added QuadraMune, an all natural immune booster to its nutraceutical product line.
  • Said Hugh Kelso, CEO, We are excited and proud to be able to deliver this product as part of our Community Immunity initiative.
  • We believe QuadraMune will prove to be an effective, long-term benefit to everyone seeking to bolster their immune systems, particularly during these extraordinary times.
  • iBrands Farms is a vertically integrated agribusiness focused on the production of hemp derived products with naturally occurring cannabinoids.

iBrands Corporation Enters Into Distribution Agreement With Medical Supply Group

Retrieved on: 
Monday, March 23, 2020
Service-Disabled Veteran-Owned Small Business, Small Business Administration

LAS VEGAS, March 23, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) ("the Company"), a diversified holding and branding company, announces that it has, through its wholly owned subsidiary iBrands Farms, entered into a distribution agreement with Standard Medical Equipment Systems respectively.

Key Points: 
  • LAS VEGAS, March 23, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) ("the Company"), a diversified holding and branding company, announces that it has, through its wholly owned subsidiary iBrands Farms, entered into a distribution agreement with Standard Medical Equipment Systems respectively.
  • Additional products included in the agreement is the unique nutraceutical product line of NanoStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol.
  • "We are thrilled to have the opportunity to collaborate with iBrands Corporation.
  • Standard Medical Equipment Systems is a certified minority (MBE) Veteran (SDVOSB) owned company certified by the Center for Veteran Enterprises, (CVE).

iBrands Corporation Enhances Net Stockholder Equity

Retrieved on: 
Wednesday, February 12, 2020
Articles, Corporate law, Stock market, Brand, Communication design, Graphic design, Product management, Business, Incorporation, Share

LAS VEGAS, Feb. 12, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces that the board has recently amended the companys Articles of Incorporation to reflect a substantial reduction of authorized shares from Unlimited Authorized to 100,000,000,000 shares.

Key Points: 
  • LAS VEGAS, Feb. 12, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (the Company), a diversified holding and branding company, announces that the board has recently amended the companys Articles of Incorporation to reflect a substantial reduction of authorized shares from Unlimited Authorized to 100,000,000,000 shares.
  • iBrands Corporation, Inc., is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential.
  • Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade.
  • Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.